Shenzhen Taili Biomedical

Shenzhen Taili Biomedical Technology Co., Ltd. (also known as Tally Biomedical) is a clinical-stage biotechnology company based in Shenzhen, China, focused on the development of next-generation immune cell therapies for solid tumors. Founded by experts with backgrounds from the University of Pennsylvania, the company utilizes its proprietary T-MAX platform to engineer CAR-T, TCR-T, and TIL therapies that can effectively penetrate and survive within the complex microenvironment of solid cancers. Its lead candidate, TL-011, is a GPC3-targeted CAR-T therapy currently in Phase 1 clinical trials for the treatment of advanced hepatocellular carcinoma. The company's pipeline also includes programs targeting mesothelin and other undisclosed antigens for various solid malignancies. Tally Biomedical is supported by prominent Chinese venture capital firms and aims to address the significant unmet medical needs in oncology through innovative cellular immunotherapy. The company operates its own GMP-compliant manufacturing facility to support clinical development and future commercialization.